530 related articles for article (PubMed ID: 9816155)
1. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
2. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.
Vanhoefer U; Yin MB; Harstrick A; Seeber S; Rustum YM
Biochem Pharmacol; 1997 Mar; 53(6):801-9. PubMed ID: 9113101
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
4. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
6. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
7. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines.
Slovak ML; Ho JP; Bhardwaj G; Kurz EU; Deeley RG; Cole SP
Cancer Res; 1993 Jul; 53(14):3221-5. PubMed ID: 8391919
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
10. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180
[TBL] [Abstract][Full Text] [Related]
11. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
12. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
13. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Wu XX; Ogawa O; Kakehi Y
Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
[TBL] [Abstract][Full Text] [Related]
15. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
16. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
18. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
19. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
Dusre L; Mimnaugh EG; Myers CE; Sinha BK
Cancer Res; 1989 Feb; 49(3):511-5. PubMed ID: 2535960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]